CSF2 and juvenile myelomonocytic leukemia: Furthermore, pharmacologic inhibition of p110δ in vitro decreased phospho-Akt and -Erk and proliferation of Shp2D61Y/+ cells, as well as the GM-CSF hypersensitivity of mononuclear cells from primary JMML patient samples [3].